Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
  • Sim, Sung Hoon
  • Kim, Jeong Eun
  • Kim, Min Hwan
  • Park, Yeon Hee
  • Kim, Jee Hyun
  • ... Lee, Gyeong-Won
  • 외 16명
Citations

WEB OF SCIENCE

2
Citations

SCOPUS

3

초록

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma (R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

키워드

HER2 positiveMetastatic breast cancerTrastuzumab biosimilarClinical trialctDNADOUBLE-BLINDPROGRESSIONRETREATMENTGUIDELINEMUTATIONSEMTANSINELAPATINIBHER2
제목
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
저자
Sim, Sung HoonKim, Jeong EunKim, Min HwanPark, Yeon HeeKim, Jee HyunSuh, Koung JinKoh, Su-JinPark, Kyong HwaKang, Myoung JooAhn, Mi SunLee, Kyoung EunKim, Hee -JunAhn, Hee KyungKim, Han JoPark, Keon UkByun, Jae HoPark, Jin HyunLee, Gyeong-WonLee, Keun SeokSohn, JoohyukJung, Kyung HaePark, In Hae
DOI
10.1016/j.breast.2022.08.002
발행일
2022-10
유형
Article
저널명
Breast
65
페이지
172 ~ 178